

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 May 2008 (02.05.2008)

PCT

(10) International Publication Number  
**WO 2008/049923 A1**

(51) International Patent Classification:

**C07H 7/00** (2006.01) **A61P 3/10** (2006.01)  
**C07H 7/04** (2006.01) **C07D 407/12** (2006.01)  
**A61K 31/70** (2006.01)

Kornblumenweg 7, 89188 Merklingen (DE). **MARTIN, Hans-Jürgen** [DE/DE]; Königsbergallee 5, 88400 Biberach (DE).

(21) International Application Number:

PCT/EP2007/061553

(74) Agents: **HAMMANN, Heinz** et al.; c/o Boehringer Ingelheim GmbH, Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(22) International Filing Date: 26 October 2007 (26.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

06123068.6 27 October 2006 (27.10.2006) EP

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicant (for all designated States except DE, US): **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Str. 173, 55216 Ingelheim am Rhein (DE).

(71) Applicant (for DE only): **BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG** [DE/DE]; Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ECKHARDT, Matthias** [DE/DE]; Kirschenweg 7, 88400 Biberach (DE). **HIMMELSBACH, Frank** [DE/DE]; Ahornweg 16, 88441 Mittelbiberach (DE). **BUTZ, Tanja, M.** [DE/DE];

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report



WO 2008/049923 A1

(54) Title: CRYSTALLINE FORM OF 4-(β-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS


(57) Abstract: The invention relates to a crystalline form of 4-(β-D-glucopyranos-1 -yI)-1-methyl-2- [4-((S)-tetrahydrofuran-3-yloxy)-benzyI]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

**Crystalline form of 4-( $\beta$ -D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments**

The invention relates to a crystalline form of 4-( $\beta$ -D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

Background of the invention

The compound 4-( $\beta$ -D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene (in the following referred to it as "compound A") is described in the international patent application WO 2005/092877 and has the chemical structure according to formula A



The compounds described therein have a valuable inhibitory effect on the sodium-dependent glucose cotransporter SGLT, particularly SGLT2. The method of manufacture of the compound A as described therein does not yield a crystalline form.

A certain pharmaceutical activity is of course the basic prerequisite to be fulfilled by a pharmaceutically active agent before same is approved as a medicament on the market. However, there are a variety of additional requirements a pharmaceutically active agent has to comply with. These requirements are based on various parameters which are connected with the nature of the active substance itself. Without being restrictive, examples of these parameters are the stability of the active agent under various environmental conditions, its stability during production of the

pharmaceutical formulation and the stability of the active agent in the final medicament compositions. The pharmaceutically active substance used for preparing the pharmaceutical compositions should be as pure as possible and its stability in long-term storage must be guaranteed under various environmental  
5 conditions. This is essential to prevent the use of pharmaceutical compositions which contain, in addition to the actual active substance, breakdown products thereof, for example. In such cases the content of active substance in the medicament might be less than that specified.

10 Uniform distribution of the medicament in the formulation is a critical factor, particularly when the medicament has to be given in low doses. To ensure uniform distribution, the particle size of the active substance can be reduced to a suitable level, e.g. by grinding. Since breakdown of the pharmaceutically active substance as a side effect of the grinding (or micronising) has to be avoided as far as possible, in  
15 spite of the hard conditions required during the process, it is essential that the active substance should be highly stable throughout the grinding process. Only if the active substance is sufficiently stable during the grinding process it is possible to produce a homogeneous pharmaceutical formulation which always contains the specified amount of active substance in a reproducible manner.

20

Another problem which may arise in the grinding process for preparing the desired pharmaceutical formulation is the input of energy caused by this process and the stress on the surface of the crystals. This may in certain circumstances lead to polymorphous changes, to amorphization or to a change in the crystal lattice. Since  
25 the pharmaceutical quality of a pharmaceutical formulation requires that the active substance should always have the same crystalline morphology, the stability and properties of the crystalline active substance are subject to stringent requirements from this point of view as well.

30 The stability of a pharmaceutically active substance is also important in pharmaceutical compositions for determining the shelf life of the particular medicament; the shelf life is the length of time during which the medicament can be administered without any risk. High stability of a medicament in the abovementioned

pharmaceutical compositions under various storage conditions is therefore an additional advantage for both the patient and the manufacturer.

The absorption of moisture reduces the content of pharmaceutically active  
5 substance as a result of the increased weight caused by the uptake of water. Pharmaceutical compositions with a tendency to absorb moisture have to be protected from moisture during storage, e.g. by the addition of suitable drying agents or by storing the drug in an environment where it is protected from moisture. Preferably, therefore, a pharmaceutically active substance should be only slightly  
10 hygroscopic.

Furthermore, the availability of a well-defined crystalline form allows the purification of the drug substance by recrystallization.

15 Apart from the requirements indicated above, it should be generally borne in mind that any change to the solid state of a pharmaceutical composition which is capable of improving its physical and chemical stability gives a significant advantage over less stable forms of the same medicament.

20 The aim of the invention is thus to provide a new, stable crystalline form of the compound A which meets important requirements imposed on pharmaceutically active substances as mentioned above.

#### Object of the invention

25 In a first aspect the present invention relates to a crystalline form of the compound A.

In a second aspect the present invention relates to the crystalline form I of the compound A having an X-ray powder diffraction pattern that comprises peaks at 18.62, 19.27 and 20.35 degrees  $2\theta$  ( $\pm 0.05$  degrees  $2\theta$ , wherein said X-ray powder  
30 diffraction pattern is made using  $\text{CuK}\alpha 1$  radiation).

In another aspect the present invention relates to the compound A wherein at least 50% of said substance is present in the form of the crystalline form as defined hereinbefore and hereinafter.

- 5 In the light of the pharmaceutical efficacy of the compound A a third aspect of the present invention relates to a pharmaceutical composition or medicament comprising a crystalline form as defined hereinbefore and hereinafter.

In a further aspect the present invention relates to a use of a crystalline form as  
10 defined hereinbefore or hereinafter for preparing a pharmaceutical composition which is suitable for the treatment or prevention of diseases or conditions which can be influenced by inhibiting sodium-dependent glucose cotransporter SGLT, preferably SGLT2.

- 15 In a further aspect the present invention relates to a use of a crystalline form as defined hereinbefore or hereinafter for preparing a pharmaceutical composition which is suitable for the treatment or prevention of metabolic disorders.

In a further aspect the present invention relates to a use of a crystalline form as  
20 defined hereinbefore or hereinafter for preparing a pharmaceutical composition for inhibiting the sodium-dependent glucose cotransporter SGLT2.

In a further aspect the present invention relates to a use of a crystalline form as defined hereinbefore or hereinafter for preparing a pharmaceutical composition for  
25 preventing the degeneration of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells.

In another aspect the present invention relates to a use of a crystalline form as defined hereinbefore and hereinafter for preparing a pharmaceutical composition for  
30 preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of liver fat in a patient in need thereof.

In a further aspect the present invention relates to a method for making the crystalline form I as defined hereinbefore and hereinafter, said method comprising the following steps:

- (a) dissolving compound A in a solvent or a mixture of solvents to form a solution, preferably a saturated, nearly saturated or supersaturated solution;
- (b) storing preferably with cooling the solution to precipitate the crystalline form out of solution and thus to yield a suspension;
- (c) isolating the precipitate from the suspension; and
- (d) drying the precipitate to remove an excess of said solvent or mixture of solvents.

10

Further aspects of the present invention become apparent to the one skilled in the art from the following detailed description of the invention and the examples.

#### Brief Description of the Figures

- 15 The Figure 1 shows an X-ray powder diffractogram of the crystalline form I. The Figure 2 shows the thermoanalysis and determination of the melting point via DSC of the crystalline form I.

#### Detailed description of the invention

- 20 Surprisingly, it has been found that there exists a crystalline form of the compound A which fulfills important requirements mentioned hereinbefore. Accordingly the present invention relates to a crystalline form of the compound A.

This crystalline form may be identified by means of their characteristic X-ray powder 25 diffraction (XRPD) patterns.

The crystalline form I is characterised by an X-ray powder diffraction pattern that comprises peaks at 18.62, 19.27 and 20.35 degrees  $2\theta$  ( $\pm 0.05$  degrees  $2\theta$ , wherein said X-ray powder diffraction pattern is made using  $\text{CuK}\alpha 1$  radiation).

30

In particular said X-ray powder diffraction pattern comprises peaks at 9.83, 18.62, 18.96, 19.27, 20.18 and 20.35 degrees  $2\theta$  ( $\pm 0.05$  degrees  $2\theta$ , wherein said X-ray powder diffraction pattern is made using  $\text{CuK}\alpha 1$  radiation).

More specifically, the crystalline form I is characterised by an X-ray powder diffraction pattern, made using CuK $\alpha$ 1 radiation, which comprises peaks at degrees 2 $\Theta$  ( $\pm 0.05$  degrees 2 $\Theta$ ) as contained in Table 1.

5

**Table 1:** X-ray powder diffraction pattern of the crystalline form I (only peaks up to 30° in 2  $\Theta$  are listed):

2 $\Theta$ [°]	d-value [Å]	Intensity I/I <sub>0</sub> [%]
4.46	19.81	22
9.83	8.99	42
10.56	8.37	5
11.68	7.57	5
13.37	6.62	3
14.70	6.02	26
15.46	5.73	20
15.94	5.56	21
16.72	5.30	2
17.73	5.00	29
18.22	4.86	22
18.33	4.84	17
18.62	4.76	72
18.96	4.68	33
19.27	4.60	52
19.74	4.49	2
20.18	4.40	30
20.35	4.36	100
21.22	4.18	20
21.91	4.05	19
22.24	3.99	10
22.53	3.94	11
23.46	3.79	24

23.58	3.77	8
23.96	3.71	2
24.37	3.65	5
24.65	3.61	12
25.05	3.55	30
25.51	3.49	10
26.25	3.39	3
26.91	3.31	3
27.09	3.29	8
28.89	3.09	3
29.29	3.05	11
29.73	3.00	2

Even more specifically, the crystalline form I is characterised by an X-ray powder diffraction pattern, made using CuK $\alpha$ 1 radiation, which comprises peaks at degrees  
 5 2 $\Theta$  ( $\pm 0.05$  degrees 2 $\Theta$ ) as shown in Figure 1.

Furthermore the crystalline form I of compound A is characterised by a melting point of about 128°C  $\pm$  3°C (determined via DSC; evaluated as onset-temperature; heating rate 10 K/min). The obtained DSC curve is shown in Figure 2.

10

The X-ray powder diffraction patterns are recorded, within the scope of the present invention, using a STOE - STADI P-diffractometer in transmission mode fitted with a location-sensitive detector (OED) and a Cu-anode as X-ray source (CuK $\alpha$ 1 radiation,  $\lambda = 1,54060 \text{ \AA}$ , 40kV, 40mA). In the Table 1 above the values "2 $\Theta$  [ $^\circ$ ]" denote the  
 15 angle of diffraction in degrees and the values "d-value [ $\text{\AA}$ ]" denote the specified distances in  $\text{\AA}$  between the lattice planes. The intensity shown in the Figure 1 is given in units of cps (counts per second).

In order to allow for experimental error, the above described 2  $\Theta$  values should be  
 20 considered accurate to  $\pm 0.05$  degrees 2  $\Theta$ . That is to say, when assessing whether a given sample of crystals of the compound A is the crystalline form I in accordance

with the invention, a  $2\Theta$  value which is experimentally observed for the sample should be considered identical with a characteristic value described above if it falls within  $\pm 0.05$  degrees  $2\Theta$  of the characteristic value.

- 5 The melting point is determined by DSC (Differential Scanning Calorimetry) using a DSC 821 (Mettler Toledo).

A further aspect of the present invention relates to a method for making the crystalline form I of the compound A as defined hereinbefore and hereinafter, said  
10 method comprising the following steps:

- (a) dissolving compound A in a solvent or a mixture of solvents to form a solution, preferably a saturated, nearly saturated or supersaturated solution;
- (b) storing the solution to precipitate the crystalline form I out of solution and thus to yield a suspension;
- 15 (c) removing the precipitate from the suspension; and
- (d) drying the precipitate to remove an excess of said solvent or mixture of solvents.

The terms "saturated" or "nearly saturated" are related to the starting material of the compound A as used in step (a). For example a solution which is saturated or nearly  
20 saturated with respect to the starting material of the compound A may be supersaturated with respect to its crystalline form.

Suitable solvents are preferably selected from the group consisting of C<sub>1-4</sub>-alkanols, water, ethylacetate, acetonitrile, acetone, diethylether and mixtures of two or more of  
25 these solvents.

More preferred solvents are selected from the group consisting of ethanol, isopropanol, ethyl acetate, diethylether, acetone, water and mixtures of two or more of these solvents.

30

Particularly preferred solvents are selected from the group consisting of ethylacetate, isopropanol, acetone and water/ethanol mixture.

Preferably the step (a) is carried at about room temperature (about 20°C) or at an elevated temperature up to about the boiling point of the solvent or mixture of solvents used.

- 5 In step (b) the solution is stored for a time sufficient to obtain a precipitate. The temperature of the solution in step (b) is about the same as or lower than in step (a). During the storing the temperature of the solution containing the compound A is preferably lowered, preferably to a temperature in the range of 20°C to 0°C or even lower. The step (b) can be carried out with or without stirring. As known to the one  
10 skilled in the art by the period of time and the difference of temperature in step (b) the size, shape and quality of the obtained crystals can be controlled. Furthermore the crystallization may be induced by methods as known in the art, for example by mechanical means such as scratching or rubbing the contact surface of the reaction vessel with e.g. a glass rod. Optionally the saturated or supersaturated solution may be  
15 inoculated with seed crystals.

In step (c) the solvent(s) can be removed from the precipitate by known methods as for example filtration, suction filtration, decantation or centrifugation.

- 20 In step (d) an excess of the solvent(s) is removed from the precipitate by methods known to the one skilled in the art as for example by reducing the partial pressure of the solvent(s), preferably in vacuum, and/or by heating above ca. 20°C, preferably in a temperature range below 80°C, even more preferably below 50°C.

- 25 The compound A may be synthesized by methods as specifically and/or generally described or cited in the international application WO 2005/092877. Furthermore the biological properties of the compound A may be investigated as it is described in the international application WO 2005/092877 which in its entirety is incorporated herein by reference.

30

The crystalline form in accordance with the invention is preferably employed as drug active substance in substantially pure form, that is to say, essentially free of other crystalline forms of the compound A. Nevertheless, the invention also embraces the

crystalline form in admixture with another crystalline form or forms. Should the drug active substance be a mixture of crystalline forms, it is preferred that the substance comprises at least 50% of the crystalline form I as described herein.

- 5 In view of their ability to inhibit the SGLT activity, the crystalline form according to the invention is suitable for the preparation of pharmaceutical compositions for the treatment and/or preventative treatment of conditions or diseases which may be affected by the inhibition of the SGLT activity, particularly the SGLT-2 activity. Therefore, the crystalline form I is particularly suitable for the preparation of
- 10 pharmaceutical compositions for prevention or treatment of diseases, particularly metabolic disorders, or conditions such as type 1 diabetes mellitus, type 2 diabetes mellitus, complications of diabetes (such as e.g. retinopathy, nephropathy or neuropathies, diabetic foot, ulcers, macroangiopathies), metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder,
- 15 insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, oedema and hyperuricaemia. The crystalline form is also suitable for the preparation of pharmaceutical compositions for preventing beta-cell degeneration such as e.g. apoptosis or necrosis of pancreatic beta cells. The crystalline form is
- 20 also suitable for the preparation of pharmaceutical compositions for improving or restoring the functionality of pancreatic cells, and also of increasing the number and size of pancreatic beta cells. The crystalline form according to the invention may also be used for the preparation of pharmaceutical compositions useful as diuretics or antihypertensives and suitable for the prevention and treatment of acute renal
- 25 failure.

By the administration of the crystalline form according to this invention an abnormal accumulation of fat in the liver may be reduced or inhibited. Therefore according to another aspect of the present invention there is provided a method for preventing,

30 slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of liver fat in a patient in need thereof characterized in that a pharmaceutical composition according to the present invention is administered. Diseases or conditions which are attributed to an abnormal accumulation of liver fat

are particularly selected from the group consisting of general fatty liver, non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hyperalimentation-induced fatty liver, diabetic fatty liver, alcoholic-induced fatty liver or toxic fatty liver.

5 In particular, the crystalline form according to the invention is suitable for the preparation of pharmaceutical compositions for the prevention or treatment of diabetes, particularly type 1 diabetes mellitus, type 2 diabetes mellitus, and/or diabetic complications.


10 In addition the crystalline form according to the invention is particularly suitable for the prevention or treatment of overweight, obesity (including class I, class II and/or class III obesity), visceral obesity and/or abdominal obesity.

The dosage required to achieve the corresponding activity for treatment or  
15 prevention usually depends on the patient, the nature and gravity of the illness or condition and the method and frequency of administration and is for the patient's doctor to decide. Expediently, the dosage may be from 1 to 100 mg, preferably 1 to 30 mg, by intravenous route, and 1 to 1000 mg, preferably 1 to 100 mg, by oral route, in each case administered 1 to 4 times a day. For this purpose, the  
20 pharmaceutical compositions according to this invention preferably comprise the crystalline form together with one or more inert conventional carriers and/or diluents. Such pharmaceutical compositions may be formulated as conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.

25


The following example of synthesis serves to illustrate a method of preparing the compound A and its crystalline form I. It is to be regarded only as a possible method described by way of example, without restricting the invention to its contents. In the following the term "ambient temperature" denotes a temperature of about 20°C.

30

**Preparation of the starting compounds:**Example I5 (2-Methyl-5-nitro-phenyl)-(4-methoxy-phenyl)-methanone

To a mixture of 2-methyl-5-nitro-benzoic acid (50 g) in dichloromethane (330 mL) is added oxalyl chloride (25.5 mL) followed by dimethylformamide (0.5 mL). The reaction mixture is stirred at ambient temperature for 14 h, then filtered and separated from all volatile constituents in a rotary evaporator. The residue is  
10 dissolved in dichloromethane (100 mL), the resulting solution is cooled to -5 °C, and anisole (31 mL) is added. Then aluminum trichloride (37.5 g) is added batchwise so that the temperature maintains below 5 °C. The solution is stirred for another 1 h at 1 to 5 °C and then poured onto crushed ice. The organic phase is separated and the aqueous phase is extracted with dichloromethane. The combined organic phases  
15 are washed with aqueous hydrochloric acid (1 mol/L), twice with aqueous sodium hydroxide solution (1 mol/L) and with brine. The organic phase is dried (sodium sulphate), the solvent is removed and the residue is recrystallised from ethanol.

Yield: 65.8 g (88% of theory); Mass spectrum (ESI<sup>+</sup>): m/z = 272 [M+H]<sup>+</sup>

20 Example II4-Amino-2-(4-methoxy-benzyl)-1-methyl-benzene

A mixture of (2-methyl-5-nitro-phenyl)-(4-methoxy-phenyl)-methanone (5.8 g) and 10% Pd on carbon (1.0 g) in ethyl acetate (200 mL) is shaken under hydrogen  
25 atmosphere (7 bar) at ambient temperature for 4.5 h. The solution is separated from the palladium catalyst by filtration and the filtrate is concentrated *in vacuo* to give a


mixture of the title compound, (5-amino-2-methyl-phenyl)-(4-methoxy-phenyl)-methanone and (5-amino-2-methyl-phenyl)-(4-methoxy-phenyl)-methanol. This compound mixture is dissolved in a mixture of acetonitrile (12 mL) and dichloromethane (8 mL) and the resulting solution is cooled in an ice-bath.

- 5 Triethylsilane (20 mL) is added followed by the slow addition of boron trifluoride diethyl etherate (16 mL). The solution is stirred for 0.5 h at 5 °C and then quenched by the addition of aqueous sodium hydroxide solution (2 mol/L). The organic phase is separated and the aqueous phase is extracted with dichloromethane. The combined organic phases are washed with brine, dried (sodium sulphate) and
- 10 concentrated *in vacuo*. The residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 9:1->2:1).

Yield: 4.0 g (82% of theory)

Mass spectrum (ESI<sup>+</sup>): m/z = 228 [M+H]<sup>+</sup>

15 Example III




4-iodo-2-(4-methoxy-benzyl)-1-methyl-benzene

- To a cooled (0 to -5 °C), stirred suspension of 4-amino-2-(4-methoxy-benzyl)-1-methyl-benzene (18.3 g) in water (70 mL) and concentrated hydrochloric acid (20
- 20 mL) is added a solution of sodium nitrite (5.8 g) in water (20 mL). The suspension is stirred until homogenous and then a solution of potassium iodide (14 g) in water (20 mL) is added. The cooling bath is removed and the solution is stirred at 40 °C for 1 h and at 70 °C for another 1.5 h. After cooling to ambient temperature, aqueous sodium thiosulfate solution is added and the resulting solution is extracted with ethyl
- 25 acetate. The combined extracts are dried (sodium sulphate) and the solvent is evaporated. The residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 19:1).

Yield: 18.1 g (66% of theory)


Mass spectrum (EI): m/z = 338 [M]<sup>+</sup>

Example IV4-(5-iodo-2-methyl-benzyl)-phenol

- 5 To an ice-cold solution of 4-iodo-2-(4-methoxy-benzyl)-1-methyl-benzene (12.5 g) in dichloromethane (70 mL) is added a solution of boron tribromide in dichloromethane (1 mol/L, 40 mL). The resulting solution is stirred in the ice-bath for 1 h and at ambient temperature overnight. The solution is then cooled in an ice bath and saturated aqueous potassium carbonate solution is added dropwise. At ambient
- 10 temperature the mixture is adjusted with aqueous hydrochloric acid (1 mol/L) to a pH of 1, the organic phase is separated, and the aqueous phase is extracted with dichloromethane. The combined organic phases are dried (sodium sulphate) and concentrated *in vacuo* to give the crude product.

Yield: 12.0 g (100% of theory)

15


Example V[4-(5-iodo-2-methyl-benzyl)-phenoxy]-tert-butyl-dimethyl-silane

- To an ice cooled solution of 4-(5-iodo-2-methyl-benzyl)-phenol (12.0 g) and
- 20 imidazole (3.2 g) in dimethylformamide (40 mL) is added tert-butyldimethylchlorosilane (6.1 g). The ice-bath is removed and the solution is stirred at ambient temperature overnight. The solution is diluted with ethyl acetate and washed twice with hydrochloric acid (1 mol/L). The organic phase is dried (sodium sulphate) and concentrated *in vacuo*. The residue is purified by chromatography on silica gel
- 25 (cyclohexane/ethyl acetate 1:0->20:1).

Yield: 9.6 g (59% of theory)

Mass spectrum (ESI):  $m/z = 439 [M+H]^+$

#### Example VI



5

#### 2-(4-Hydroxybenzyl)-4-(1-methoxy-β-D-glucopyranos-1-yl)-1-methyl-benzene

A solution of [4-(5-iodo-2-methyl-benzyl)-phenoxy]-tert-butyl-dimethyl-silane (4.3 g) in dry tetrahydrofuran (50 mL) is cooled to -80 °C under argon atmosphere.

Butyllithium (1.6 mol/L in hexane, 7.0 mL) is added dropwise and the resultant

10 solution is stirred for 45 min at -78 °C. Then a solution of 2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone (6.0 g) in tetrahydrofuran (30 mL) chilled to -80 °C is added via transfer canula. The resulting solution is stirred for 3 h at -78 °C and then quenched with acetic acid in water (1% acetic acid, 100 mL). The organic layer is separated and the aqueous layer is extracted with ethyl acetate. The combined

15 organic phases are washed with brine, dried (sodium sulphate) and concentrated.


The residue is taken up in methanol (30 mL) and treated with methanesulfonic acid (20 μL). The resulting solution is stirred at ambient temperature overnight.

Triethylamine (2 mL) is added and the solution is concentrated under reduced pressure. Ethyl acetate is added and the resulting mixture is washed with aqueous

20 sodium hydrogencarbonate solution, dried (sodium sulphate) and concentrated to give the crude product.

Yield: 3.4 g (89% of theory)

Mass spectrum (ESI):  $m/z = 389 [M-H]^-$


Example VII

2-(4-Acetoxybenzyl)-1-methyl-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-benzene

- 5 A solution of 2-(4-hydroxybenzyl)-4-(1-methoxy-β-D-glucopyranos-1-yl)-1-methylbenzene (3.4 g) and triethylsilane (2.9 mL) in a mixture of acetonitrile (100 mL) and dichloromethane (40 mL) is cooled to -20 °C. Boron trifluoride diethyl etherate (1.7 mL) is added dropwise and the solution is allowed to warm to 0 °C. After 30 min of stirring, aqueous potassium hydroxide solution (4 mol/L, 9 mL) is added and the
- 10 resulting solution is stirred for 15 min at ambient temperature. The solution is adjusted to pH 5 by addition of hydrochloric acid (1 mol/L) and extracted with ethyl acetate. The combined organic phases are washed with brine, dried (sodium sulphate) and concentrated. The residue is dissolved in dichloromethane (50 mL) and pyridine (5 mL), acetic anhydride (5 mL) and 4-dimethylaminopyridine (0.1 g)
- 15 are consecutively added. After stirring at ambient temperature for 4 h, aqueous sodium bicarbonate solution is added and the resulting mixture is stirred for 10 min. Then the organic phase is separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with hydrochloric acid (1 mol/L), dried (sodium sulphate) and concentrated. The residue is recrystallized from ethanol
- 20 to give the pure product.

Yield: 1.8 g (37% of theory)


Mass spectrum (ESI<sup>+</sup>): m/z = 588 [M+NH<sub>4</sub>]<sup>+</sup>

Example VIII4-(β-D-glucopyranos-1-yl)-2-(4-hydroxy-benzyl)-1-methyl-benzene

A solution of 2-(4-acetoxybenzyl)-1-methyl-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-benzene (1.8 g) in a mixture of methanol (30 mL) and tetrahydrofuran (15 mL) is treated with aqueous potassium hydroxide solution (4 mol/L, 3.8 mL). The reaction solution is stirred at ambient temperature for 30 min and then neutralized with hydrochloric acid (1 mol/L). The resulting mixture is concentrated under reduced pressure, diluted with aqueous sodium bicarbonate solution and extracted with ethyl acetate. The combined organic phases are dried (sodium sulphate) and concentrated.

Yield: 1.18 g (100% of theory)

Mass spectrum (ESI<sup>+</sup>): m/z = 378 [M+NH<sub>4</sub>]<sup>+</sup>

**Preparation of the compound A:**

4-(β-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene

- 5 (R)-3-(4-methylphenylsulfonyloxy)-tetrahydrofuran (4.9 g) is added to a mixture of 4-(β-D-glucopyranos-1-yl)-2-(4-hydroxy-benzyl)-1-methyl-benzene (4.9 g) and cesium carbonate (6.6 g) in dimethylformamide (50 mL). The mixture is stirred at 60 °C for 8 h, before more cesium carbonate (0.7 g) and (R)-3-(4-methylphenyl-sulfonyloxy)-tetrahydrofuran (0.5 g) are added. After an additional 14 h stirring at 80 °C, the
- 10 mixture is cooled to ambient temperature, diluted with ethyl acetate and washed with brine. The organic phase is dried (sodium sulphate) and the solvent is removed. The residue is purified by chromatography on silica gel (dichloromethane/methanol 1:0 -> 4:1).

Yield: 2.68 g (46% of theory)

- 15 Mass spectrum (ESI<sup>+</sup>): m/z = 448 [M+NH<sub>4</sub>]<sup>+</sup>

**Preparation of the crystalline form I:**

- 4-(β-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-
- 20 benzene (2.6 g, obtained as described above) is dissolved in ethyl acetate (10 mL) upon heating up to about 50 °C. The solution is allowed to cool slowly (about 1 to 3 h) to about 20 °C. After 48 h the crystalline form I is isolated as white crystals by filtration. An excess of the solvent is removed by storing the crystals at elevated temperature (40 to 50 °C) for about 3 to 4 h at reduced pressure.

**Patent Claims**

1. Crystalline form of 4-( $\beta$ -D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene.  
5
2. The crystalline form I of 4-( $\beta$ -D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene having an X-ray powder diffraction pattern that comprises peaks at 18.62, 19.27 and 20.35 degrees  $2\Theta$  ( $\pm 0.05$  degrees  $2\Theta$ ), wherein said X-ray powder diffraction pattern is made using  $\text{CuK}\alpha 1$  radiation.  
10
3. The crystalline form I according to claim 2, wherein the X-ray powder diffraction pattern further comprises peaks at 9.83, 18.96 and 20.18 degrees  $2\Theta$  ( $\pm 0.05$  degrees  $2\Theta$ ), wherein said X-ray powder diffraction pattern is made using  $\text{CuK}\alpha 1$  radiation.  
15
4. 4-( $\beta$ -D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene wherein at least 50% of said substance is present in the form of the crystalline form in accordance with claim 1, 2 or 3.
- 20 5. A pharmaceutical composition comprising the crystalline form in accordance with claim 1, 2 or 3.
6. Use of the crystalline form in accordance with claim 1, 2 or 3 for preparing a pharmaceutical composition which is suitable for the treatment or prevention of  
25 diseases or conditions which can be influenced by inhibiting the sodium-dependent glucose cotransporter SGLT.
7. Use of the crystalline form in accordance with claim 1, 2 or 3 for preparing a pharmaceutical composition which is suitable for the treatment or prevention of  
30 metabolic disorders, in particular of a metabolic disorder selected from the group consisting of type 1 and type 2 diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose

metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, oedema and hyperuricaemia.

5 8. Use of the crystalline form in accordance with claim 1, 2 or 3 for preparing a pharmaceutical composition for inhibiting the sodium-dependent glucose cotransporter SGLT2.

9. Use of the crystalline form in accordance with claim 1, 2 or 3 for preparing a  
10 pharmaceutical composition for preventing the degeneration of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells.

10. Use of the crystalline form in accordance with claim 1, 2 or 3 for preparing a  
15 pharmaceutical composition for preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of liver fat in a patient in need thereof.

11. A method for making the crystalline form in accordance with claim 1, 2 or 3, said method comprising the following steps:

- 20 (a) dissolving 4-( $\beta$ -D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene in a solvent or a mixture of solvents to form a solution;
- (b) storing the solution to precipitate the crystalline form in accordance with claim 1, 2 or 3 out of solution and thus to yield a suspension;
- (c) isolating the precipitate from the suspension; and
- 25 (d) drying the precipitate to remove an excess of said solvent or mixture of solvents.

Figure 1: X-ray powder diffraction pattern of the crystalline form I





Figure 2: DSC diagram of the crystalline form I



INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2007/061553

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> INV. C07H7/00 C07H7/04 A61K31/70 A61P3/10 C07D407/12		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) C07H A61K A61P C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internat		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/092877 A (BOEHRINGER INGELHEIM INT [DE]; BOEHRINGER INGELHEIM PHARMA [DE]; HIMME) 6 October 2005 (2005-10-06) cited in the application page 75 compound 22 -----	1-11
<input type="checkbox"/> Further documents are listed in the continuation of Box C.		
<input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents :		
*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed		*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
Date of the actual completion of the international search  6 February 2008		Date of mailing of the international search report  14/02/2008
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  de Nooy, Arjan

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2007/061553

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005092877 A	06-10-2005	AR 048041 A1	22-03-2006
		AU 2005225511 A1	06-10-2005
		BR PI0508830 A	14-08-2007
		CA 2557801 A1	06-10-2005
		JP 2007522143 T	09-08-2007
		JP 2007246544 A	27-09-2007
		KR 20060133021 A	22-12-2006

---